top of page

What is a Botanical Drug?

A botanical drug is composed of either a single plant or a blend of multiple plants. According to the US FDA, the entire combination is regarded as the active pharmaceutical ingredient (API) for a botanical drug.

 

Developing herbal medicines with established safety and effectiveness into prescription botanical drugs in the US is an efficient drug development route, comparing to the process of isolating a single molecular from a plant.

about the
American Botanical Drug Association
Why We Exist

Why We Exist?

The FDA's “Botanical Drug Development Guidance for Industry" paves the way for botanical products such as herbal medicines and cannabis-derived products to evolve into prescription drugs. Utilizing the FDA botanical drug IND process to develop herbal medicines with established safety and effectiveness is a streamlined approach to drug development  ...
Why We exist.jpg
ABDA Small.jpg

Who We Are?

The American Botanical Drug Association (ABDA) is a tax-exempt nonprofit organization under section 501(c)(3).  ABDA is dedicated to promoting the progression of natural herbal formulations into prescription medicines, specifically as FDA-approved Botanical Drugs in the United States ...
Who We Are?

Our Focus

Modern herbal medicines are typically available in pill or capsule formats. These products have already shown their safety and effectiveness through extensive daily use by a significant population. Identifying herbal medicines with established safety and effectiveness that have the potential to be developed into prescription botanical drugs in the United States represents an efficient drug development pathway ...
TCM.jpg
Focus
Business Model


Registration open 

in

Jan 2023
Leadership

LEADERSHIP

David Allen (1).jpg

David Allen

President

Gupta (1).jpg

Purdeep Gupta

SVP, R&D

ABoulet_edited.jpg

Andre Boulet

SVP, Canada

mmexport1590351628768.jpg

Pai-Ping Fan

SVP, United Kingdom

PHOTO-2022-07-01-11-53-15.jpg

Simon Tang

General Counsel

G%C3%B6ran-Olsson_edited.jpg

Goran Olsson

CFO

FRANCIS2.JPG

Francis Hadji-Minaglou

SVP, France

戴慧芳.jpg

Mary Brown

SVP, China

黄勇_edited_edited.jpg

Yong Huang

Managing Director

Botanical Drug Impact Fund

Yuan Chun-Su (1).jpg

Chun-Su, Yuan

SVP, Scientific Affairs

JoergG1.jpg

Joerg Gruenwald

SVP, Germany

sree photo.jpg

Tirunagari Sreedhar

VP, India Central

JGT photo.jpg

John Tobin

SVP, Global BD

Don%20Brown_edited.png

Donal Brown

SVP, Manufacturing & Quality

Alex.jpg

Alex Semprini

SVP, New Zealand

Stevie Council_photo_edited.jpg

Steve Coucil

SVP, Strategic Initatives

Botanical Drugs Impact Fund
Fund
BDIF.png
The Botanical Drug Impact Fund (BDIF) serves as an industry fund designed as a collaborative platform for the advancement of research and development in the field of botanical medicines. Within this platform, both institutions and individuals have the opportunity to actively contribute to the progress of disease treatment using herbal medicines by making contributions to the fund. Contributors are also able to select specific products or areas of disease treatment that align with their interests.

How We Do It?

Numerous medicinal herbal formulations from various regions around the world have shown both efficacy and safety within their respective markets. These herbal formulations are typically available in the form of pills or capsules and hold great potential for botanical drug development. However, the drug development process is intricate and time-consuming, often requiring a breadth of expertise that small entities may lack.

The Botanical Drug Impact Fund serves as a collective platform aimed at fostering collaborative efforts in advancing the research and development of herbal medicines into prescription botanical drugs. This endeavor seeks to address the treatment of challenging medical conditions for which effective chemical drugs are currently lacking. Through BDIF, individual investors have the opportunity to participate in substantial drug development initiatives, contributing to the advancement of medical science.
funding2.jpg

Botanical Drugs vs COVID

A herbal product, comprising a blend of multiple herbs, is currently in the initial stages of the US FDA Investigational New Drug (IND) process. This product is intended for the treatment of COVID-19 by bolstering the human immune system ...
Covid.jpg
Botanical Drug 3.webp

Botanical Drugs vs Diabetes

Abstract: Non-alcoholic fatty liver disease (NAFLD) can cause insulin resistance (IR) and diabetes. Our previous studies have demonstrated that Jian-Gan-Xiao-Zhi decoction (JGXZ) could be effective for the treatment of NAFLD and IR. However, the ...

Botanical Drugs vs Cancer

A botanical product, consisting of a blend of several herbs, is currently in the initial stages of the US FDA Investigational New Drug (IND) process. This product is intended for increasing the white blood cell count in patients undergoing chemotherapy treatment ...
ABDA-English
ABDA-中文
ABDA-Deutsche
ABDA-Française
ABDA-한국어
ABDA-日本語
ABDA-עִברִית
ABDA-Española
ABDA-عربى
ABDA-ngôn ngữ tiếng Việt
ABDA-हिंदी
ABDA-Bahasa Melayu
ABDA-Português
ABDA-ไทย
ABDA-Bahasa Indonesia
ABDA-русский
bottom of page